Table 2 Sorafenib administration in the safety population (N = 331)
Duration of treatment | |
 Missing | 12 (3.6) |
  ≤ 4 weeks | 21 (6.3) |
  > 4 and ≤8 weeks | 37 (11) |
  > 8 and ≤12 weeks | 51 (15) |
  > 12 and ≤16 weeks | 23 (6.9) |
  > 16 and ≤20 weeks | 17 (5.1) |
  > 20 and ≤24 weeks | 19 (5.7) |
  > 24 and ≤28 weeks | 15 (4.5) |
  > 28 weeks | 136 (41) |
Treatment duration (weeks) for available patients | |
 Number | 319 |
 Mean ± SD | 29.54 ± 24.79 |
 Median (range) | 22.30 (0.1 to 116.1) |
Average daily dose (mg) | |
 Number | 204 |
 Mean ± S D | 776.2 ± 83.6 |
 Median (range) | 800 (332 to 818) |
Total dose (mg) | |
 Number | 204 |
 Mean ± SD | 133,512.3 ± 115,060.0 |
 Median (range) | 198,350 (800 to 600,800) |
Dose intensity (%) | |
 Number | 204 |
 Mean ± SD | 96.5 ± 11.8 |
 Median (range) | 100 (26 to 102) |
Actual days on study drug (excluding off days) | |
 Number | 204 |
 Mean ± SD | 171.4 ± 146.3 |
 Median (range) | 127.5 (1 to 751) |
Initial sorafenib dose level | |
 Number | 331 |
 400 mg | 4 (1.2) |
 600 mg | 1 (0.3) |
 800 mg | 326 (98) |
Total subjects with dose interruptions ticked, yes | 7 (2.1) |
Total subjects with dose modification ticked, yes | 27 (8.2) |
Total subjects with dose increase, yes | 13 (3.9) |
Total subjects with dose reduction, yes | 21 (6.3) |